Background & aim: Polycystic ovary syndrome (PCOS) affects approximately 10–15% of women of reproductive age and is a leading cause of anovulation and infertility. PCOS is frequently accompanied by hyperandrogenism, insulin resistance, and altered body composition. Androgen-induced mouse models reproduce…
Background & aim: Subcutaneous pump delivery of the GLP1-receptor-agonist exenatide reduced body weight and improved glycemia in the DIO mouse. Basal-bolus administration conferred advantage over basal alone. This mode of incretin-based therapy offers an alternative to conventional intermittent dosing and…
Background & aim: The current understanding of diabetic kidney disease (DKD) has significant gaps regarding the underlying pathogenesis. In this study, we aimed to characterize the temporal progression of DKD using a state-of-the-art mouse model of hypertension-accelerated disease, integrating kidney…
Background & aim: Myocardial fibrosis (MF), a hallmark of structural cardiac remodelling, drives disease progression across most forms of heart failure and plays a central role in heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, effective treatments…
Background & aim: Obesity, hyperglycemia and hypertension are critical risk factors for development of diabetic kidney disease (DKD). While emerging evidence suggests that glucagon-like peptide-1 receptor (GLP1R) agonists improve cardiovascular and renal outcomes in type 2 diabetes patients, their mode…
Background & aim: NLT-101 is a first-in-class compound that functions by proximity engagement with a target in the nuclear envelope that mediates its activity. NLT-101 is in preclinical development for metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis driven indications. The present…
Background & aim: The glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist tirzepatide is currently approved for the treatment of obesity and type 2 diabetes. In a recent phase 2b trial (SYNERGY-NASH) in patients with metabolic-dysfunction…
Background & aim: The long-acting glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved for the treatment of type 2 diabetes and obesity. Recently, semaglutide has been reported to improve liver histopathological outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis…
